Advertisement
UK markets close in 6 hours 40 minutes
  • FTSE 100

    7,969.52
    +37.54 (+0.47%)
     
  • FTSE 250

    19,815.58
    +4.92 (+0.02%)
     
  • AIM

    741.44
    -0.67 (-0.09%)
     
  • GBP/EUR

    1.1684
    +0.0015 (+0.13%)
     
  • GBP/USD

    1.2593
    -0.0045 (-0.36%)
     
  • Bitcoin GBP

    56,098.99
    +543.89 (+0.98%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • DOW

    39,760.08
    +477.75 (+1.22%)
     
  • CRUDE OIL

    81.76
    +0.41 (+0.50%)
     
  • GOLD FUTURES

    2,216.30
    +3.60 (+0.16%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,497.95
    +20.86 (+0.11%)
     
  • CAC 40

    8,244.41
    +39.60 (+0.48%)
     

Takeda's $64 Billion Offer Bolstered by Shire's Results

Takeda's $64 Billion Offer Bolstered by Shire's Results

Shire Plc’s results topped expectations for its latest quarter, bolstering Takeda Pharmaceutical Co.’s case in selling its $64 billion takeover offer to investors. Revenue at Shire totaled about $3.8 billion in the first three months of the year, more than the $3.7 billion analysts expected, driven by growth in the company’s immunology drugs. About 72 percent of Shire’s sales came from its rare-disease division, a business coveted by Takeda.